Review: What to do when all RBCs are incompatible - Serologic aspects

Immunohematology

Volumn 20, Issue 3, 2004, Pages 147-160

  Nance, Sandra Taddie ^a   Arndt, Patricia A ^a  

^a AMERICAN RED CROSS BLOOD SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; ANTIGEN; AUTOANTIBODY; BLOOD GROUP ANTIGEN; BLOOD GROUP KN ANTIGEN; CHROMIUM 51; COLD AGGLUTININ; COLD REACTIVE AUTOANTIBODY; HIGH FREQUENCY ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY ASSAY; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; AUTOLOGOUS ERYTHROCYTE; BLOOD GROUP INCOMPATIBILITY; BLOOD GROUP KN SYSTEM; BLOOD TRANSFUSION; CELL ASSAY; CHEMOLUMINESCENCE; CHEMOLUMINESCENCE TEST; CLINICAL ARTICLE; COLD AGGLUTININ SYNDROME; COMPUTER ANALYSIS; COMPUTER PROGRAM; DIAGNOSTIC KIT; ERYTHROCYTE; FEMALE; HUMAN; HUMAN CELL; IMMUNOADSORPTION; IN VITRO STUDY; MALE; MONOCYTE; MONOCYTE MONOLAYER ASSAY; MONOLAYER CULTURE; MULTIPLE ANTIBODY SPECIFICITY; PRIORITY JOURNAL; REVIEW; SEROLOGY; SICKLE CELL ANEMIA; SYNDROME; TECHNIQUE;

ABO BLOOD-GROUP SYSTEM; ADULT; AGED; AUTOANTIBODIES; BLOOD GROUP INCOMPATIBILITY; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; MALE; MIDDLE AGED; SEROLOGIC TESTS;

EID: 4444265627     PISSN: 0894203X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Reid ME, Toy PT. Simplified method for recovery of autologous red blood cells from transfused patients. Am J Clin Pathol 1983;79:364-6.
2. Brown DJ. A rapid method for harvesting autologous red cells from patients with hemoglobin S disease. Transfusion 1988;28:21-3.
3. Laine EP, Leger RM, Arndt PA, et al. In vitro studies on the impact of transfusion on the detection of alloantibodies after autoadsorption. Transfusion 2000;40:1384-7.
4. Allogeneic red cell adsorption for removal of warm autoantibody. In: Immunohematology methods and procedures. 1st ed. The American National Red Cross 1993:47-51.
5. Liew YW, Duncan N. Polyethylene glycol in autoadsorption of serum for the detection of alloantibodies (letter). Transfusion 1995;35:713.
6. Chiaroni J, Touinssi M, Mazet M, deMicco P, Ferrera V. Adsorption of autoantibodies in the presence of LISS to detect alloantibodies underlying warm autoantibodies. Transfusion 2003;43:651-5.
7. Barron CL, Brown MB. The use of polyethylene glycol (PEG) to enhance the adsorption of autoantibodies. Immunohematology 1997;13:119-22.
8. Judd WJ, Dake L. PEG adsorption of autoantibodies causes loss of concomitant alloantibody. Immunohematology 2001;17:82-5.
9. Leger RM, Garratty G. Evaluation of methods for detecting alloantibodies underlying warm autoanti-bodies. Transfusion 1999;39:11-6.
10. Branch DR, Petz LD. Detecting alloantibodies in patients with autoantibodies (editorial). Transfusion 1999;39:6-10.
11. Cheng C-K, Wong ML, Lee AW. PEG adsorption of autoantibodies and detection of alloantibodies in warm autoimmune hemolytic anemia. Transfusion 2001;41:13-7.
12. Leger RM, Ciesielski D, Garratty G. Effect of storage on antibody reactivity after adsorption in the presence of polyethylene glycol (letter). Transfusion 1999;39:1272-3.
13. Storry JR, Mallory D. Misidentification of anti-Vel due to inappropriate use of prewarming and adsorption techniques. Immunohematology 1994;10:83-6.
14. Judd WJ. Controversies in transfusion medicine. Prewarmed techniques: Con. Transfusion 1995;35:271-5.
15. Mallory D. Controversies in transfusion medicine. Prewarmed tests: Pro - why, when, and how - not if. Transfusion 1995;35:268-70.
16. Garratty G. Attack on prewarmed tests-Too much hot air (letter)? Transfusion 1996;36:192.
17. Judd WJ, Steiner EA, Knaff P, Davenport RD. Failure to detect potentially significant antibodies in prewarmed tests (abstract). Transfusion 1995;35:(Suppl):68S.
18. Kilsby MA. Comparison of prewarmed techniques: with and without enhancements (abstract). Transfusion 1999;39(Suppl):104S.
19. Leger RM, Garratty G. Weakening or loss of antibody reactivity after prewarm technique. Transfusion 2003;43:1611-4.
20. Petz LD, Garratty G. Immune hemolytic anemias. 2nd ed. Philadelphia: Churchill Livingstone, 2004:133-65,352-6.
21. Reid M, Lomas-Francis C. The blood group antigen factsbook. 2nd ed. San Diego: Elsevier Academic Press, 2004.
22. Issitt PD, Anstee DJ. Applied blood group serology. 4th ed. Durham: Montgomery 1998.
23. Daniels G. Human blood groups. 2nd ed. Oxford: Blackwell Science, 2002.
24. Garratty G. Evaluating the clinical significance of blood group alloantibodies that are causing problems in pretransfusion testing. Vox Sang 1998;74:285-90.
25. Arndt PA, Garratty G. A retrospective analysis of the value of monocyte monolayer assay results for predicting the clinical significance of blood group alloantibodies. Transfusion 2004 (in press).
26. Daniels G, Poole J, de Silva M, et al. The clinical significance of blood group antibodies. Transfus Med 2002;12:287-95.
27. Leger RM. In vitro cellular assays and other approaches used to predict the clinical significance of red cell alloantibodies: a review. Immunohematology 2002;18:65-70.
28. Reid ME, Oyen R, Marsh WL. Summary of the clinical significance of blood group alloantibodies. Semin Hematol 2000;37:197-216.
29. Nance S. Review: measuring red cell survival and determining the clinical significance of red cell antibodies. Immunohematology 1995;11:31-8.
30. Engelfriet CP, Overbeeke MAM, Dooren MC, Ouwehand WH, von dem Borne AEGKr. Bioassays to determine the clinical significance of red cell alloantibodies based on Fc receptor-induced destruction of red cells sensitized by IgG. Transfusion 1994;34:617-26.
31. Garratty G. Factors affecting the pathogenicity of red cell auto- and alloantibodies. In: Nance SJ, ed. Immune destruction of red blood cells. Arlington, VA: American Association of Blood Banks, 1989;109-69.
32. Garratty G. Predicting the clinical significance of alloantibodies and determining the in vivo survival of transfused red cells. In: Judd WJ, Barnes A, eds. Clinical and serological aspects of transfusion reactions: a technical workshop. Washington DC: American Association of Blood Banks, 1982:91-119.
33. Engelfriet CP, Ouwehand WH. ADCC and other cellular bioassays for predicting the clinical significance of red cell alloantibodies. Baillieres Clin Haematol 1990;3:321-37.
34. Hadley A, Wilkes A, Poole J, Arndt P, Garratty G. A chemiluminescence test for predicting the outcome of transfusing incompatible blood. Transfus Med 1999;9:337-42.
35. Schanfield MS, Stevens JO, Bauman D. The detection of clinically significant erythrocyte alloantibodies using a human mononuclear phagocyte assay. Transfusion 1981;21:571-6.
36. Branch DR, Gallagher MT, Mison AP, Sy Siok Hian AL, Petz LD. In vitro determination of red cell alloantibody significance using an assay of monocyte-macrophage interaction with sensitized erythrocytes. Br J Haematol 1984;56:19-29.
37. Nance SJ, Arndt P, Garratty G. Predicting the clinical significance of red cell alloantibodies using a monocyte monolayer assay. Transfusion 1987;27:449-52.
38. Garratty G. Predicting the clinical significance of red cell antibodies with in vitro cellular assays. Transfus Med Rev 1990;IV:297-312.
39. Zupańska B, Gronkowska A, Ziemski M. Comparison of activity of peripheral monocytes and splenic macrophages in the monocyte monolayer assay. Vox Sang 1995;68:241-2.
40. Nance SJ, Arndt PA, Garratty G. The effect of fresh normal serum on monocyte monolayer assay reactivity. Transfusion 1988;28:398-9.
41. Church A, Mallory D, Kavitsky D, Nance S. Impact of complement in the monocyte monolayer assay (abstract). Transfusion 1997;37(Suppl):27S.
42. 2 in short-term monocyte-macrophage assays (letter). Transfusion 1985;25:399.
43. a demonstrating a change in its clinical significance. Vox Sang 1988;55:171-5.
44. 51Cr, flow cytometric, IgG subclass, and monocyte erythrophagocytosis assays (abstract). Transfusion 1986;26:545.
45. a. Am J Clin Pathol 1991;95:87-90.
46. Nance S, Scandone P, Fassl L, et al. Monocyte monolayer assay (MMA) results are affected by transfusion of incompatible red cells (abstract). Transfusion 1997;37(Suppl):37S.
47. a (letter). Immunohematology 1991;7:107.
48. Pearson HA, Richards VL, Wylie BR, et al. Assessment of clinical significance of anti-Ge in an untransfused man. Transfusion 1991;31:257-9.
49. Issitt PD, Gutgsell NS, Hervis L. Some stored antibodies give unreliable results in the monocyte monolayer assay (letter). Transfusion 1988;28:399-400.
50. Wren MR, Issitt PD. The monocyte monolayer assay and in vivo antibody activity (abstract). Transfusion 1986;26:548.
51. Gibson M, Devenish A, Daniels GL, Contreras M. A transfusion problem in a thalassaemic infant with anti-Lu6 (abstract). Ann Mtg Br Blood Transfus Soc 1983;27.
52. Issitt PD, Valinsky JE, Marsh WL, DiNapoli J, Gutgsell NS. In vivo red cell destruction by anti-Lu6. Transfusion 1990;30:258-60.
53. Yahalom V, Ellis MH, Poole J, et al. The rare Lu:-6 phenotype in Israel and the clinical significance of anti-Lu6. Transfusion 2002;42:247-50.
54. 51Cr radiolabeled survival studies in a patient with anti-Lu12 (abstract). Transfusion 1988;28(Suppl): 37S.
55. a (letter). Transfusion 1988;28:289-90.
56. a and anti-M in a chronically transfused sickle cell patient. Immunohematology 1988;4:71-4.
57. ab in the second example of a Tc(a-b-) individual (abstract). Transfusion 1989;29 (Suppl):17S.
58. Judd WJ, Oberman HA, Silenieks A, Steiner EA. Clinical significance of anti-Lan (letter). Transfusion 1984;24:181.
59. a. Vox Sang 1995;69:135-7.
60. a. Transfusion 1995;35:63-7.
61. 51Cr red cell survival of serologically incompatible red cell units. Transfusion 1985;25:34-8.
62. a: an erythrocytic antigen of high frequency. Vox Sang 1979;36:182-5.
63. Gutgsell NS, Issitt LA, Issitt PD. Transfusion of antigen-positive, serologically-incompatible blood in immunized patients, based solely on the results of a monocyte monolayer assay (MMA) (abstract). Transfusion 1988;28:32S.
64. a. Immunohematology 1995;11:81-4.
65. Zupanska B, Brojer E, McIntosh J, Seyfried H, Howell P. Correlation of monocyte-monolayer assay results, number of erythrocyte-bound IgG molecules, and IgG subclass composition in the study of red cell alloantibodies other than D. Vox Sang 1990;58:276-80.
66. Hildebrandt M, Hell A, Etzel R, Genth R, Salama A. Determination and successful transfusion of anti-Gerbich-positive red blood cells in a patient with a strongly reactive anti-Gerbich antibody. Infusionsther Transfusionsmed 2000;27:154-6.
67. a (abstract). Transfusion 1992;32:23S.
68. a (abstract). Transfusion 1995;35:61S.
69. a. Transfusion 1999;39:948-50.
70. Kobuszewski M, Wallace M, Moulds M, et al. Clinical significance of anti-Lu8 in a patient who received Lu:8 red cells (abstract). Transfusion 1988;28(Suppl):37S.
71. a (letter). Transfusion 1986;26:543-4.
72. a: report of two cases and review of the literature. Transfusion 2004;44:197-201.
73. b assessed by flow cytometry. Immunohematology 1997;13:93-6.
74. a (Cromer-related blood group antigen)-incompatible renal transplantation. Vox Sang 1998;74:106-8.
75. a. Transfusion 1982;22:189-93.
76. International Committee for Standardization in Haematology. Recommended method for radioisotope red-cell survival studies. Br J Haematol 1980;45:659-66.